Director/PDMR Shareholding

RNS Number : 7360T
GlaxoSmithKline PLC
16 October 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

1,605.036

£15.2750

831.931

£15.2750

2,740.030

£15.2750

4,439.830

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

9,616.827

£15.2750

  

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

1,249.200

£15.2750

1,600.015

£15.2750

1,529.167

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

4,378.382

£15.2750

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

319.540

£15.2750

402.745

£15.2750

1,147.102

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,869.387

£15.2750

 

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

2,716.836

£15.2750

2,942.442

£15.2750

2,427.360

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

8,086.638

£15.2750

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

605.675

£15.2750

660.007

£15.2750

563.370

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,829.052

£15.2750

  

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$41.02

415.800

$41.02

83.187

$41.02

641.729

$41.02

1,036.064

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,176.780

$41.02

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

993.680

£15.2750

1,160.005

£15.2750

1,094.561

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

3,248.246

£15.2750

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, HR

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

1,324.911

£15.2750

1,460.009

£15.2750

1,207.230

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

3,992.150

£15.2750

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

766.560

£15.2750

840.010

£15.2750

756.529

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2,363.099

£15.2750

 

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

       

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$41.02

1,132.956

$41.02

1,314.438

$41.02

1,154.472

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

3,601.866

$41.02

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

2,755.819

£15.2750

3,400.038

£15.2750

3,138.824

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

9,294.681

£15.2750

  

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£15.2750

169.685

£15.2750

160.363

£15.2750

150.569

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

480.617

£15.2750

 

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

 

n/a

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEQLFFDBFXFBX

Companies

GSK (GSK)
UK 100

Latest directors dealings